Algert Global LLC Has $469,000 Stock Position in Replimune Group, Inc. (NASDAQ:REPL)

Algert Global LLC lessened its stake in Replimune Group, Inc. (NASDAQ:REPL) by 49.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 42,763 shares of the company’s stock after selling 41,270 shares during the quarter. Algert Global LLC’s holdings in Replimune Group were worth $469,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Nisa Investment Advisors LLC boosted its stake in Replimune Group by 10,304.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock worth $45,000 after purchasing an additional 4,946 shares during the period. Point72 DIFC Ltd acquired a new position in shares of Replimune Group during the second quarter worth about $57,000. Arizona State Retirement System bought a new position in shares of Replimune Group during the second quarter worth about $108,000. Quest Partners LLC raised its position in Replimune Group by 30.4% in the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock valued at $122,000 after buying an additional 3,150 shares during the last quarter. Finally, Russell Investments Group Ltd. bought a new stake in Replimune Group in the 1st quarter valued at approximately $140,000. Institutional investors own 92.53% of the company’s stock.

Insider Activity

In related news, insider Konstantinos Xynos sold 7,246 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 8.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on REPL. Roth Mkm initiated coverage on shares of Replimune Group in a report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $17.00 price target on shares of Replimune Group in a research note on Friday, November 22nd. BMO Capital Markets increased their price objective on shares of Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a research note on Friday, November 22nd. Roth Capital raised Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. Finally, JPMorgan Chase & Co. increased their price target on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, September 24th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Replimune Group has an average rating of “Buy” and an average target price of $17.00.

Replimune Group Price Performance

Shares of NASDAQ REPL opened at $14.08 on Friday. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. The business’s 50 day moving average price is $11.89 and its two-hundred day moving average price is $10.00. The company has a market cap of $963.31 million, a PE ratio of -4.62 and a beta of 1.19. Replimune Group, Inc. has a twelve month low of $4.92 and a twelve month high of $17.00.

Replimune Group (NASDAQ:REPL) last posted its earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. On average, analysts predict that Replimune Group, Inc. will post -2.99 EPS for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.